

Post Test, Evaluation, and Credit Application

Progress in Prevention of IFIs & Promise of New Diagnostic Techniques

On-demand Webinar

(Release date: 4/14/2009 Expiration date: 4/15/2010)

Your professional title: Physician Pharmacist Other _____

Your practice setting: Teaching hospital Community hospital LTAC
Other _____

INSTRUCTIONS FOR CREDIT

1. Review the On-Demand Webinar in its entirety.
2. Print and complete the Post Test, Evaluation, and Credit Application form.
3. Mail the completed Post Test, Evaluation, and Credit Application form to
Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807
OR
Fax to (908) 235-4222.

Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and Credit Application form.

Your evaluation and suggestions will help improve the quality of future continuing education activities. Please answer the following general questions, provide written comments, and evaluate the individual faculty. Additional space for your comments and suggestions is available. Thank you for your cooperation.

POST TEST (Please check the most appropriate answer)

1. Which diagnostic test can be used to identify specific *Candida* species?

- β -D-glucan Assay
- PNA FISH™
- Galactomannan Assay
- Gram stain

2. Which antifungal agent lacks in vitro activity against *Aspergillus*?

- Voriconazole
- Fluconazole
- Posaconazole
- Caspofungin

3. Which azole exhibits activity against Zygomycetes?

- Fluconazole
- Itraconazole
- Voriconazole
- Posaconazole

POST TEST (Please check the most appropriate answer)			
<p>4. Limitations of the β-D-glucan assay include all of the following EXCEPT:</p> <p><input type="checkbox"/> Does not detect <i>Cryptococcus</i> infections</p> <p><input type="checkbox"/> Does not detect <i>Candida</i> infections</p> <p><input type="checkbox"/> Does not detect <i>Zygomycetes</i> infections</p> <p><input type="checkbox"/> False-positives associated with the use of gauze and dialysis filters</p>			
<p>5. Which of the following has not been associated with false-positive results when using the serum galactomannan assay to detect invasive aspergillosis?</p> <p><input type="checkbox"/> Presence of other fungi</p> <p><input type="checkbox"/> Use of piperacillin/tazobactam</p> <p><input type="checkbox"/> Prior antifungal therapy</p> <p><input type="checkbox"/> Solid organ transplantation</p>			
<p>6. Which of the following CT scan findings is an early sign of pulmonary aspergillosis?</p> <p><input type="checkbox"/> Air crescent</p> <p><input type="checkbox"/> Halo sign</p> <p><input type="checkbox"/> Nodules >1 cm</p> <p><input type="checkbox"/> Multiple nodules</p>			
<p>7. Which of the following does not accurately describe formulations of amphotericin B?</p> <p><input type="checkbox"/> Concentration-dependent activity</p> <p><input type="checkbox"/> Fungicidal</p> <p><input type="checkbox"/> Broad spectrum of activity</p> <p><input type="checkbox"/> IV and oral formulations available</p>			
<p>8. Serum concentration monitoring would not be necessary when administering which of the following azoles?</p> <p><input type="checkbox"/> Fluconazole</p> <p><input type="checkbox"/> Itraconazole</p> <p><input type="checkbox"/> Voriconazole</p> <p><input type="checkbox"/> Posaconazole</p>			
<p>9. The echinocandins do not exhibit in vitro activity against which of the following organisms?</p> <p><input type="checkbox"/> <i>Candida glabrata</i></p> <p><input type="checkbox"/> <i>Candida krusei</i></p> <p><input type="checkbox"/> <i>Cryptococcus neoformans</i></p> <p><input type="checkbox"/> <i>Aspergillus fumigatus</i></p>			
<p>10. According to NCCN guidelines, which of the following is not recommended for prophylaxis of HSCT recipients with significant graft-versus-host disease?</p> <p><input type="checkbox"/> Fluconazole</p> <p><input type="checkbox"/> Lipid formulation of amphotericin B</p> <p><input type="checkbox"/> Voriconazole</p> <p><input type="checkbox"/> Posaconazole</p>			

LEARNING OBJECTIVES: Were the learning objectives met?	Yes	Somewhat	No
Assess the appropriate use of antifungal prophylaxis in immunocompromised patients			
Evaluate the utility of the latest diagnostic techniques for early detection of IFIs			
If you answered 'No' to any objective, please explain.			

FACULTY	Excellent	Good	Fair	Poor
Pranatharthi H. Chandrasekar, MD				
Teaching ability				
Knowledge and expertise in the subject				
Richard H. Drew, PharmD, MS, BCPS				
Teaching ability				
Knowledge and expertise in the subject				

OVERALL EVALUATION	Yes	Somewhat	No
1. This activity met my expectations.			
2. The content was relevant to my practice.			
3. This activity was fair and balanced.			
4. This activity was without commercial bias.			
If you answered "No" to 3 or 4, please explain.			

LEARNING FORMAT	Yes	Somewhat	No
1. The course format enhanced achievement of learning objectives.			
2. The format was easy to follow and understand.			

ACTIVITY MANAGEMENT	Yes	Somewhat	No
1. On-demand Webinar was easy to access.			
2. On-demand Webinar format was conducive to learning.			

PRACTICE APPLICATION
1. What aspects of this activity were most relevant to your practice?
2. Please list one diagnostic tool that can be used for early detection of an IFI that you learned in this activity.
3. Do you intend to make changes to your practice based on participation in this activity? If yes, please specify.
4. What aspects of IFIs do you need to learn more about to improve your practice performance?

DO YOU HAVE (1) ANY SUGGESTIONS FOR IMPROVING THIS ACTIVITY or (2) ANY ADDITIONAL COMMENTS?

POST ACTIVITY SURVEY (Please check all that apply)

Center for Independent Healthcare Education is dedicated to promoting a spirit of lifelong learning and continuous professional development. To that end, we are interested in understanding your specific barriers and challenges. Please take a few moments to complete this Post Activity Survey. Please note that your individual responses will be kept confidential.

Are you familiar with the guidelines recently released by the Infectious Diseases Society of America on the management of aspergillosis and candidiasis?

- Yes, I have read them
- Yes, but I have not read both of them carefully
- No, I am not aware of them

What are the greatest challenges you face in incorporating management guidelines into your practice?

- Getting access to the guidelines
- Finding time to read the guidelines
- Understanding how to apply the guidelines to daily practice
- Other (please explain) _____

Do you consider yourself well-equipped to be an equal partner of the healthcare team when managing patients with IFIs?

- I have knowledge of the guidelines and recent clinical research and know what to do
- I have knowledge of the guidelines and recent clinical research but do not know how to implement this knowledge in clinical practice
- I need more information on the guidelines and clinical research
- Other (please specify) _____

What are the tools and competencies you need to appropriately prevent and manage IFIs?

- Knowledge of current guidelines
- Knowledge of the most common fungal pathogens
- Strategies for prevention and infection control
- Strategies for selecting the most appropriate antifungal agent
- Practical guide on the use of the latest diagnostic techniques
- Criteria that can be used for empiric antifungal selection
- Strategies to use when initial antifungal treatment fails
- Other (please specify) _____

CREDIT APPLICATION (Please Print)

Name and Degree _____

Address _____

City _____ State _____ ZIP _____

E-mail address _____ May we contact you by e-mail? Yes No

Type of credit requested ACPE AMA

I certify that I participated in *Progress in Prevention of IFIs & Promise of New Diagnostic Techniques*.

Signature _____ **Date** _____

For questions regarding accreditation of this activity, please contact Center for Independent Healthcare Education at info@jointsponsor.com.